Postow, Michael

Publications

Sort by

Co-Author Network

selected publications

The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. Journal of translational medicine. 2020 Academic Article GET IT
Times cited: 1
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 37
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 245
TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Comment GET IT
Times cited: 10
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 178
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma research. 2020 Academic Article GET IT
Times cited: 27
Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Editorial Article GET IT
Times cited: 2
First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 212
Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. Ophthalmology. 2019 Academic Article GET IT
Times cited: 30
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. The Lancet. Oncology. 2019 Guideline GET IT
Times cited: 181
Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 238
Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy: A Report of 2 Cases. 2019 GET IT
Times cited: 16
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Guideline GET IT
Times cited: 20
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. Journal for immunotherapy of cancer. 2018 Guideline GET IT
Times cited: 18
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. 2018 GET IT
Times cited: 12
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. 2018 GET IT
Times cited: 105
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1137
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science translational medicine. 2018 Academic Article GET IT
Times cited: 170
Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Comment GET IT
Times cited: 22
Immune-related Adverse Events in Cancer Patients. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2018 Review GET IT
Times cited: 20
The brim of uncertainty in adjuvant treatment of melanoma. The Lancet. Oncology. 2018 Comment GET IT
Times cited: 3
Participatory implementation science to increase the impact of evidence-based cancer prevention and control. Cancer causes & control : CCC. 2018 Academic Article GET IT
Times cited: 146
Reply to M. Horiguchi et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Letter GET IT
Times cited: 1
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. The New England journal of medicine. 2018 Review GET IT
Times cited: 3395
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 Academic Article GET IT
Times cited: 418
High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018 Academic Article GET IT
Times cited: 299
Clinical Development of PD-1 in Advanced Melanoma. Cancer journal (Sudbury, Mass.). 2018 Review GET IT
Times cited: 45
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. Journal of translational medicine. 2017 Conference Paper GET IT
Times cited: 18
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. Journal of translational medicine. 2017 Editorial Article GET IT
Times cited: 29
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. Journal for immunotherapy of cancer. 2017 Academic Article GET IT
Times cited: 108
A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. 2017 GET IT
Times cited: 29
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2017 Academic Article GET IT
Times cited: 3116
Treatment of advanced melanoma - A changing landscape. Revista da Associacao Medica Brasileira (1992). 2017 Review GET IT
Times cited: 20
Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 21
Reduced-dose ipilimumab with standard-dose pembrolizumab: is less more?. The Lancet. Oncology. 2017 Comment GET IT
Times cited: 3
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. Ophthalmology. 2017 Academic Article GET IT
Times cited: 125
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer treatment reviews. 2017 Review GET IT
Times cited: 134
Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. 2017 GET IT
Times cited: 59
Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone. 2017 GET IT
Times cited: 6
Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. Annals of surgical oncology. 2017 Academic Article GET IT
Times cited: 43
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. 2017 GET IT
Times cited: 109
Better use of immune checkpoint inhibition: Treating higher risk patients and examining neurologic toxicity. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Editorial Article GET IT
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Journal of immunotherapy (Hagerstown, Md. : 1997). 2017 Academic Article GET IT
Times cited: 18
Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation. Cancer journal (Sudbury, Mass.). 2017 Review GET IT
Times cited: 31
Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Comment GET IT
Times cited: 24
Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment cell & melanoma research. 2016 Review GET IT
Times cited: 117
Recent advances in understanding antitumor immunity. F1000Research. 2016 Review GET IT
Times cited: 514
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 23
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA oncology. 2016 Review GET IT
Times cited: 698
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016 Academic Article GET IT
Times cited: 319
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Academic Article GET IT
Times cited: 265
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. The oncologist. 2016 Review GET IT
Times cited: 208
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma research. 2016 Academic Article GET IT
Times cited: 35
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy. 2016 Review GET IT
Times cited: 142
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. 2016 GET IT
Times cited: 137
Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head & neck. 2016 Academic Article GET IT
Times cited: 80
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. European journal of cancer. 2016 Review GET IT
Times cited: 389
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. Current oncology reports. 2016 Review GET IT
Times cited: 40
Reply to N. Lowy et al and to J. Dhanda et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Letter GET IT
Irradiation and immunotherapy: From concept to the clinic. Cancer. 2016 Review GET IT
Times cited: 74
Checkpoint Blockade for the Treatment of Advanced Melanoma. Cancer treatment and research. 2016 Review GET IT
Times cited: 39
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. 2015 Academic Article GET IT
Times cited: 218
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Review GET IT
Times cited: 1230
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. British journal of haematology. 2015 Academic Article GET IT
Times cited: 16
Liver resection and ablation for metastatic melanoma: A single center experience. Journal of surgical oncology. 2015 Academic Article GET IT
Times cited: 23
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. International journal of radiation oncology, biology, physics. 2015 Academic Article GET IT
Times cited: 351
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. 2015 GET IT
Times cited: 19
Immune checkpoint modulation: rational design of combination strategies. Pharmacology & therapeutics. 2015 Review GET IT
Times cited: 76
Managing immune checkpoint-blocking antibody side effects. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Review GET IT
Times cited: 359
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 104
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmacogenomics and personalized medicine. 2014 Review GET IT
Times cited: 107
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. International journal of radiation oncology, biology, physics. 2014 Review GET IT
Times cited: 144
Current options and future directions in the systemic treatment of metastatic melanoma. The Journal of community and supportive oncology. 2014 Academic Article GET IT
Times cited: 6
Checkpoint blocking antibodies in cancer immunotherapy. FEBS letters. 2013 Review GET IT
Times cited: 225
Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer immunology research. 2013 Review GET IT
Times cited: 136
Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. Clinical sarcoma research. 2012 Academic Article GET IT
Times cited: 17
Mucosal melanoma: pathogenesis, clinical behavior, and management. Current oncology reports. 2012 Review GET IT
Times cited: 121
A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management. 2012 GET IT
Times cited: 1
Chemotherapy in the Rwandan countryside: universal issues a world away. Annals of internal medicine. 2012 Academic Article GET IT
Times cited: 1
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer journal (Sudbury, Mass.). 2012 Review GET IT
Times cited: 63
Therapeutic implications of KIT in melanoma. Cancer journal (Sudbury, Mass.). 2012 Review GET IT
Times cited: 36
A piece of my mind. The ice cream man. JAMA. 2011 Academic Article GET IT

more ...

less ...

Background

education and training

B.S., Duke University 2008
M.D., New York University School of Medicine 2007

Contact

full name

Michael Postow

VIVO Weill Cornell Medical College

Michael Postow Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name